Compare CHMI & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | PYPD |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 73.0M |
| IPO Year | 2013 | 2020 |
| Metric | CHMI | PYPD |
|---|---|---|
| Price | $2.59 | $4.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.75 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 226.8K | 76.9K |
| Earning Date | 11-06-2025 | 02-11-2026 |
| Dividend Yield | ★ 15.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $40,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.73 | N/A |
| P/E Ratio | $134.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $2.30 |
| 52 Week High | $3.68 | $4.63 |
| Indicator | CHMI | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 73.55 |
| Support Level | $2.47 | $4.10 |
| Resistance Level | $2.78 | $4.63 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 40.32 | 75.00 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.